Clinical Trials Logo

Stage IIIC Breast Cancer AJCC v7 clinical trials

View clinical trials related to Stage IIIC Breast Cancer AJCC v7.

Filter by:

NCT ID: NCT00390455 Completed - Clinical trials for Recurrent Breast Carcinoma

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Start date: September 15, 2006
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies fulvestrant and lapatinib to see how well they work compared to fulvestrant and a placebo in treating postmenopausal women with stage III or stage IV breast cancer that is hormone receptor-positive. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of breast cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether fulvestrant is more effective with or without lapatinib in treating breast cancer.

NCT ID: NCT00376688 Completed - Clinical trials for Recurrent Breast Carcinoma

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Start date: July 11, 2006
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.